The synergistic antitumor effects of berberine α-hydroxy-β- decanoylethyl sulfonate with hydroxycamptothecine and its effect on topoisomerase

Yaoxue Xuebao

Volumn 46, Issue 4, 2011, Pages 390-394

  Lin, Jing ^a   Wang, Xi ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Agarose gel electrophoresis; Berberine hydroxy decanoylethyl sulfonate; DNA topoisomerase; Hydroxycamptothecine; Synergistic effect

Indexed keywords

ANTINEOPLASTIC AGENT; BERBERINE ALPHA HYDROXY BETA DECANOYLETHYL SULFONATE; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); HYDROXYCAMPTOTHECINE; UNCLASSIFIED DRUG;

AGAR GEL ELECTROPHORESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CYTOTOXICITY; DNA SUPERCOILING; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; IN VITRO STUDY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BERBERINE; CAMPTOTHECIN; CELL LINE, TUMOR; CELL PROLIFERATION; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DRUG SYNERGISM; HUMANS; TOPOISOMERASE I INHIBITORS;

EID: 79958781027     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Jia BZ. Ion pair compound of berberine and houttuyfonate: CN, 200510136655.2 [P]. 2007-07-04.
2. Li B, Zhu WL, Chen KX. Advances in the study of berberine and its derivatives [J]. Acta Pharm Sin, 2008, 43: 773-787.
3. Wang ZH, Lin J. Effects of berberine on the proliferation and differentiation of HL-60 cells [J]. Chin Pharmacol Bull, 2004, 20: 1305-1308. (Pubitemid 40260584)
4. Yang J, Lin J. Inhibition of mice implanted tumor by berberine [J]. China Pharm, 2009, 18: 4-5.
5. Kruczynski A, Barret JM, Van Hille B. Decreased nucleotide excision repair activity and alterations of topoisomerase IIalpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II [J]. Clin Cancer Res, 2004, 10: 3156-3168. (Pubitemid 38619697)
6. Yang YD, Chen YG, Wu H, et al. Antitumor activity of compound Mirabijalone B and its effect on DNA topoisomerases [J]. Chin Pharmacol Bull, 2009, 25: 1345-1349.
7. Center for Drug Evaluation, State Food and Drug Administration. Guidance on non-clinical study of cytotoxic antitumor drug [EB/OL]. State Food and Drug Administration, 2006 [2008-04-01] http://www.cde.org.cn/zdyz.do?method= largePage&id=31
8. Chou TC. Preclinical versus clinical drug combination studies [J]. Leuk Lymphoma, 2008, 49: 2059-2080.
9. Chou TC, Motzer RJ, Tong Y, et al. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design [J]. J Natl Cancer Inst, 1994, 86: 1517-1524. (Pubitemid 24330215)
10. Li TK, Bathory E, Lavoie EJ, et al. Human topoisomerase I poisoning by protoberberine: potential roles for both drug-DNA and drug-enzyme interactions [J]. Biochemistry, 2000, 39: 7107-7116.
11. Kim SA, Kwon Y, Kim JH, et al. Induction of topoisomerase II - mediated DNA cleavage by a protobererine alkaloid, berberrubine [J]. Biochemistry, 1998, 37: 16316-16324. (Pubitemid 28536268)
12. Lin J, Peng HY, Wang X, et al. Antitumor effects of berberine α-hydroxy β-decanoylethyl sulfonate in vitro [J]. Pharm Clin Chin Mater Med, 2011, 27: 15-18.
13. Lin J, Peng HY. Apoptosis of B16 melanoma cells induced by berberine α-hydroxy-β-decanoylethyl sulfonate [J]. Chin Pharmacol Bull, 2010, 26: 1630-1634.